Literature DB >> 23736862

Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners.

James A Simon1, Rossella E Nappi, Sheryl A Kingsberg, Ricardo Maamari, Vivien Brown.   

Abstract

OBJECTIVE: This study aims to determine the emotional and physical impact of vaginal atrophy on North American postmenopausal women and their male partners.
METHODS: A weighted sample of 1,000 married or cohabiting North American postmenopausal women aged 55 to 65 years with vaginal discomfort and 1,000 male partners of postmenopausal women aged 55 to 65 years who experienced vaginal discomfort participated in the Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) online survey to determine the impact of vaginal discomfort and local estrogen therapy on intimacy, relationships, and women's self-esteem.
RESULTS: Vaginal discomfort caused most surveyed North American women to avoid intimacy (58%), experience loss of libido (64%), and experience pain associated with sex (64%). Most surveyed North American men also believed that vaginal discomfort caused their partners to avoid intimacy (78%), experience loss of libido (52%), and find sex painful (59%). Approximately 30% of North American women and men cited vaginal discomfort as the reason they ceased having sex altogether. North American women who used local estrogen therapy to treat their vaginal discomfort reported less painful sex (56%), more satisfying sex (41%), and improved sex life (29%). Most men reported looking forward to having sex (57%) because of their partner's use of local estrogen therapy.
CONCLUSIONS: Local estrogen therapy ameliorates the negative impact of vaginal atrophy on the intimate relationships of North American postmenopausal women and their male partners. Additional education and awareness efforts about the symptoms of and available treatments for vaginal atrophy may be of further benefit to North American partners.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23736862     DOI: 10.1097/GME.0b013e318295236f

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  18 in total

1.  Predictors of impact of vaginal symptoms in postmenopausal women.

Authors:  Mary M Hunter; Sanae Nakagawa; Stephen K Van Den Eeden; Miriam Kuppermann; Alison J Huang
Journal:  Menopause       Date:  2016-01       Impact factor: 2.953

2.  Management of Potential Long-Term Toxicities in Breast Cancer Patients.

Authors:  C C O'Sullivan; K J Ruddy
Journal:  Curr Breast Cancer Rep       Date:  2016-10-13

3.  Factors associated with developing vaginal dryness symptoms in women transitioning through menopause: a longitudinal study.

Authors:  L Elaine Waetjen; Sybil L Crawford; Po-Yin Chang; Barbara D Reed; Rachel Hess; Nancy E Avis; Sioban D Harlow; Gail A Greendale; Sheila A Dugan; Ellen B Gold
Journal:  Menopause       Date:  2018-10       Impact factor: 2.953

4.  The Relative Burden of Menopausal and Postmenopausal Symptoms versus Other Major Conditions: A Retrospective Analysis of the Medical Expenditure Panel Survey Data.

Authors:  Annlouise R Assaf; Andrew G Bushmakin; Nina Joyce; Michael J Louie; Michael Flores; Margaret Moffatt
Journal:  Am Health Drug Benefits       Date:  2017-09

5.  Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.

Authors:  G Constantine; S Graham; D J Portman; R C Rosen; S A Kingsberg
Journal:  Climacteric       Date:  2014-09-25       Impact factor: 3.005

Review 6.  Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene.

Authors:  Risa Kagan; Steven R Goldstein; James H Pickar; Barry S Komm
Journal:  Ther Clin Risk Manag       Date:  2016-04-07       Impact factor: 2.423

7.  Randomized, Double-Blind, Placebo-Controlled Study of Modified Erzhi Granules in the Treatment of Menopause-Related Vulvovaginal Atrophy.

Authors:  Ranran Chen; Dianrong Song; Wei Zhang; Guanwei Fan; Yingqiang Zhao; Xiumei Gao
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-14       Impact factor: 2.629

8.  Genitourinary syndrome of menopause: effects on related factors, quality of life, and self-care power.

Authors:  Hediye Karakoç; Arzu Kul Uçtu; Nebahat Özerdoğan
Journal:  Prz Menopauzalny       Date:  2019-04-09

9.  Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study.

Authors:  W H Utian; R Maamari
Journal:  Climacteric       Date:  2013-11-05       Impact factor: 3.005

10.  Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Authors:  James A Simon; Corrado Altomare; Susannah Cort; Wei Jiang; JoAnn V Pinkerton
Journal:  J Womens Health (Larchmt)       Date:  2017-10-24       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.